Table 1 characteristics and quality assessment of the included studies
Study | Year | Tumor type | Survival outcome | Country | Pathological stage | Number of patients | Follow-up period (mean/range, months) | Cut-off for PDPN positive | NOS Quality Score | |
|---|---|---|---|---|---|---|---|---|---|---|
PDPN+ | PDPN- | |||||||||
Hanako Suzuki | 2011 | LUSC | OS,PFS | Japan | I–III | 16 | 24 | 40 | >25% | 7 |
Juan Li | 2017 | LUSC | OS | China | I-IV | 60 | 22 | 19.5 | >80% | 7 |
Kyuichi Kadota | 2010 | LUSC | OS | Japan | I–III | 12 | 38 | till 80 | >30% | 8 |
Liyi Xie | 2018 | LUSC | PFS | China | I-IV | 28 | 42 | 53.4 | >75% | 6 |
Takeo Ito | 2008 | LUSC | OS,PFS | Japan | IB | 69 | 67 | 43.9 | >10% | 8 |
Shotaro Iwakiri | 2009 | LUSC | OS | Japan | I–IIIA | 40 | 42 | 60 | weak and strong, none staining | 6 |
Yoichiro IKOMA | 2015 | LUSC | OS | Japan | I–III | 32 | 71 | 51.7 | ≥10% | 8 |
Yoshihisa Shimada | 2009 | LUSC | OS | Japan | I–III | 107 | 55 | 60 | >10% | 8 |